NYSE: DGX · Diagnostics & Research
Quest Diagnostics (DGX) fair value: undervalued or overvalued?
As of 15 Nov 2026, Faircurve's model values Quest Diagnostics (DGX) at $314.32 a share. The stock last closed at $262.21, which puts the model's fair value 19.9% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Quest Diagnostics Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 15 Nov 2026 moved the fair value from $302.79 to $314.32 (+3.8%).
What the model makes of itThe price of $262.21 is 19.9% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 9 Feb 2027. Options prices imply a move of about 8% either way over the next month. On the model's Scorecard Leaders list since 4 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give DGX?
The calibrated range for DGX over 63 trading days is $240.27 to $287.42. It sits around the last close, and its width comes from the volatility that DGX's own options imply (26% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $248.07 to $386.54. In 75% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 15 Nov 2026
Quest Diagnostics Incorporated (DGX) is a premier provider of diagnostic testing, information and related services. It was founded in 1967 and is headquartered in Secaucus, New Jersey, serving clients both domestically and internationally.
Faircurve's model gives Quest Diagnostics a fair value of $314.32 a share on 15 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $302.79, so the model's fair value moved +3.8%. The calibrated range over 63 trading days is $235.83 to $287.15. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices: 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Quest Diagnostics scores 74 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Earnings quality is the strongest, at 90, with free cash flow at 1.22x net income. Stability scores 87, with five-year EBITDA margin downside volatility of 1.9 pts against a peer median of 11.4 pts. The balance sheet scores 42, with net debt at 2.38x EBITDA. The model compares the company with Illumina, Mettler-Toledo, IQVIA, Medpace, Waters, Revvity and Agilent. Labcorp is also a comparable company, but it has no verdict on this date.
Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does DGX report earnings, and how has the stock reacted?
Quest Diagnostics's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 6.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. DGX's 30 day implied volatility works out to about 7.6% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DGX's last 8 reports, ignoring direction, was 4.4%.
What the options market has priced for a month's move in DGX
How does DGX score on business quality?
Quest Diagnostics's overall quality score is 74 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 75 | 9.9%ROIC | -12.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 1.22xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 70 | 11.8%Revenue growth, trailing | 20.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 63 | 1.9%Net buybacks / market value | 0.9% |
| Balance sheetNet debt to EBITDA and interest coverage. | 42 | 2.38xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 87 | 1.9 ptsEBITDA margin downside volatility, 5y | 11.4 pts |
How does DGX compare with similar companies?
The companies in diagnostics & research closest to Quest Diagnostics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
| ILMN Illumina, Inc. | $198.00 | $172.96 | -12.6% | Fairly valued |
| MTD Mettler-Toledo International Inc. | $1,727.26 | $1,679.36 | -2.8% | Fairly valued |
| IQV IQVIA Holdings Inc. | $264.73 | $335.69 | +26.8% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
| WAT Waters Corporation | $453.42 | $337.75 | -25.5% | Overvalued |
| RVTY Revvity, Inc. | $148.85 | $185.05 | +24.3% | Undervalued |
| A Agilent Technologies, Inc. | $172.92 | $176.09 | +1.8% | Fairly valued |
What the comparable companies' multiples alone would give for DGX, the peer-implied price, is $1,477.66 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
Quest Diagnostics at a glance
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally.
- Market value
- $28.6B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $12.6B
- Consensus revenue growth, next fiscal year
- +9.5%
- Analysts with estimates
- 11
- Beta to the US market
- -0.13
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. DGX was among them.
How the fair value is worked out: the model prices Quest Diagnostics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for DGX was $302.79. As of 15 Nov 2026 it is $314.32, a change of +3.8%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Quest Diagnostics's valuation
Is Quest Diagnostics stock undervalued or overvalued?
On Faircurve's model, DGX reads as Undervalued as of 15 Nov 2026. The model's fair value is $314.32 a share against a last close of $262.21, a gap of +19.9%.
What is DGX's fair value?
$314.32 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $248.07 to $386.54.
What price range does the model give DGX?
$240.27 to $287.42 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Quest Diagnostics report earnings next?
The next report is scheduled for 9 Feb 2027. Companies can move their dates.
How much has DGX moved on past earnings reports?
Across its last 8 reports the median two session move was 4.4%, ignoring direction. The largest was +9.4% around the report of 10 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for DGX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on DGX
The model has an idea open on DGX under Scorecard Leaders since 4 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DGX with their outcomes. A free account is enough.